Other. Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the “Company” or the “Registrant”) and U.S. Bank Trust Company, National Association (the “ Indenture ”), governing the Company's 0.625% Convertible Senior Notes due 2031 (the “ Notes ”), as a result of the Special Dividend that was declared by the Company’s board on September 16, 2026, the conversion rate per $1,000 principal amount of Notes has been incre…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

CEO — Joseph Ciaffoni: The CEO and other senior officers are departing as part of a merger, which is a significant management change but driven by the transaction rather than internal failure.

Entry into a Material Definitive Agreement. Credit Agreement On November 2, 2026 (the “ Closing Date ”), the Combined Company and certain of its subsidiaries (collectively, the “ Loan Parties ”) entered into a Credit Agreement (the “ Credit Agreement ”) by and among the Combined Company, as the borrower, the other Loan Parties, as guarantors, the financial institutions from time to time party thereto as lenders, and Citibank, N.A. (“ Citi ”), as agent for the lenders and for itself as lender,…

Completion of Acquisition or Disposition of Assets. The disclosure in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference. Subject to the terms and conditions of the Merger Agreement, at the Effective Time, and as a result of the Merger, each share of common stock of Supernus, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time (other than Excluded Shares, as defined in the Merger Agreement) was converted into the…

Results of Operations and Financial Condition. On October 29, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended September 30, 2026. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Other Events. As previously reported, on August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (the “Indivior”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus Pharmaceuticals, Inc., a Delaware corporation (“Supernus”) and Artemis Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Indivior (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement…

Other Events. As previously disclosed, on August 1, 2026, Indivior and Artemis Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Indivior (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus Pharmaceuticals, Inc., a Delaware corporation (“Supernus”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Supernus (the “Merger”),…

Termination of a Material Definitive Agreement. On September 9, 2026, Indivior UK Limited ("Indivior") and Reckitt Benckiser Healthcare (UK) Limited ("RB") entered into a Deed of Variation and Termination relating to that certain Copacker Supply Agreement dated December 23, 2014, as was amended on March 29, 2019 (the "Copacker Supply Agreement"). RB manufactures SUBOXONE® Tablets and SUBUTEX® Tablets for Indivior pursuant to the terms of the Copacker Supply Agreement. Pursuant to the Deed of…

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (“Indivior”) and Artemis Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Indivior (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus Pharmaceuticals, Inc., a Delaware corporation (“Supernus”). The Merger Agreement provides that, upon the terms and subject to the conditions se…

Results of Operations and Financial Condition. On August 3, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended June 30, 2026. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Chief Scientific Officer — Dr. Christian Heidbreder: The position of Chief Scientific Officer is being eliminated and Dr. Heidbreder's employment will terminate by the end of 2026.

Other. On May 4, 2026 the Company issued a press release announcing that it had entered into an accelerated share repurchase agreement (the “ASR Agreement”) with an investment bank counterparty (the “Counterparty Bank”) to repurchase $175.0 million (the “Prepayment Amount”) of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), as part of the Company’s previously announced $400 million share repurchase program (the “Share Repurchase Program”). The full text…

Results of Operations and Financial Condition. On April 30, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended March 31, 2026. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The disclosure set forth in

Termination of a Material Definitive Agreement On March 17, 2026, the Company used a portion of the proceeds of the Convertible Notes Offering to prepay all outstanding principal, accrued interest, and associated fees under that Note Purchase Agreement fir st made as of November 4, 2024, by and among by and among RBP Global Holdings Limited, Indivior Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto, as amended by that…

Entry Into a Material Definitive Agreement. Indenture On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “ Company ”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031 (the “ Notes ”; the “ Convertible Notes Offering ”). The Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture ”), dated as of March 17, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “ Trustee ”). Pursuant to the pu…

The Notes were issued to the initial purchasers in reliance upon Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”), in transactions not involving any public offering. The Notes were resold by the initial purchasers to persons whom the initial purchasers reasonably believed are “qualified institutional buyers,” as defined in, and in accordance with, Rule 144A under the Securities Act. Any shares of the Company’s common stock that may be issued upon conversion o…

Other Events. On March 12, 2026, the Company announced the pricing of its offering of 0.625% convertible senior notes due 2031 (the “Notes”). A copy of the press release is filed as 99.1 to this Current Report on Form 8-K. Neither this Current Report on Form 8-K nor the press release constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company’s common stock, if any, issuable upon conversion of the Notes.

Other Events. On March 12, 2026, the Company announced the launch of its proposed offering of convertible senior notes due 2031 (the “Notes”). A copy of the press release is filed as 99.1 to this Current Report on Form 8-K. Neither this Current Report on Form 8-K nor the press release constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company’s common stock, if any, issuable upon conversion of the Notes.

Results of Operations and Financial Condition. On February 26, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended December 31, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Other Events. Description of Indivior U.S. Capital Stock Indivior U.S. has one class of securities registered under Section 12 of the Exchange Act: its common stock. The following description of Indivior U.S.’s capital stock is a summary. This summary is subject to the General Corporation Law of the State of Delaware (the “ DGCL ”) and the complete text of the Certificate and Bylaws which are incorporated herein by reference. General Indivior U.S.’s authorized capital stock consists of 700,00…

Director: The filing discloses the continuation of the existing board and executive team following a corporate domestication (redomestication) event, rather than a departure, hire, or election.

Unregistered Sale of Equity Securities. The information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under the heading “Note Purchase Agreement” under